Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 13/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 7/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496007 | 0.94 | AVPR1A (0.42) | AVPR1AIDH1OXTRAVPR2 | |
| SCHEMBL1496255 | 0.92 | IDH1 (0.38) | AVPR1AIDH1OXTRAVPR2WNT1 | |
| SCHEMBL1496081 | 0.90 | AVPR1A (0.45) | AVPR1AOXTRAVPR2 | |
| SCHEMBL1495943 | 0.90 | IDH1 (0.46) | AVPR1AIDH1OXTR | |
| SCHEMBL1495996 | 0.88 | AVPR1A (0.45) | AVPR1AOXTRAVPR2 | |
| SCHEMBL1495930 | 0.85 | AVPR1A (0.40) | AVPR1AIDH1OXTRAVPR2 | |
| SCHEMBL18944285 | 0.85 | AVPR1A (0.40) | AVPR1AIDH1OXTRAVPR2 | |
| SCHEMBL2628963 | 0.84 | AVPR1A (0.41) | AVPR1AIDH1OXTRAVPR2 | |
| SCHEMBL12832107 | 0.84 | AVPR1A (0.40) | AVPR1AIDH1OXTRAVPR2 | |
| SCHEMBL12832110 | 0.83 | IDH1 (0.48) | AVPR1AIDH1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292621-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2011-03-09 | — | — | EP | claimed |